Elise Rundén-Pran
Senior Scientist / Head of Section for the Health Effects Laboratory
+47 63 89 82 37
+47 970 15 315
Environmental Chemistry and Health Effects
Kjeller
erp@nilu.no
Dr. Elise Rundén-Pran is senior scientist and section leader for Health Effects Laboratory and ERT registered toxicologist.
She has extensive experience in toxicology, nanotoxicology, nanosafety, cell cultures, 3D-cellular models, nanogenotoxicology, DNA damage, intracellular cell death signaling, microscopy (confocal, TEM), immunohistochemistry, tissue slice cultures and neurodegeneration.
She was part of the Centre for Excellence in Molecular Neurobiology and DNA repair (UiO) for several years (PhD and Postdoc). She is experienced with human risk assessment and regulatory toxicology, partner leader in EURONANOMED II projects GEMNS and INNOCENT, and NILU project leader for several projects funded by EU and NFR. She has extensive experience in GLP, and is appointed member of the national committee for approval of European registered toxicologists (ERT), The Norwegian Scientific Committee for Food and Environment, and member of the national expert group for toxicology.
The Health Effects Laboratory is certified for Good Laboratory Practice (GLP) for in vitro human toxicity studies. The laboratory is among the leading laboratories in Europe in nanotoxicology and nanosafety, and main areas of interest are genotoxicity, carcinogenicity in vitro, epigenetics, advanced in vitro models, regulatory aspects of nanosafety, high-throughput approach to toxicity testing, intelligent testing strategy and adverse outcome pathways.
Elise Rundén-Pran has 145 publications at NILU:
2025
2025
2025
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2021
2021
2021
2021
2021
2021
2020
2020
2020
Risk governance of emerging technologies demonstrated in terms of its applicability to nanomaterials
2020
2020
2020
2020
2019
2019
2019
2019
2018
2017
2017
2017
2017
2017
2017
2017
2016
2016
2016
2016
2015
2015
2015
2014
2012
2011
2010
2009
2009
2009
Glutamate Oxaloacetate Transaminase Nanoparticles targeted to the Brain for Neuroprotection in Ischemic Stroke (GOTTARG)
The project will develop and test the first targeted and long-acting nanomedicine with neuroprotective properties for ischemic stroke, with potential application in other neurological diseases. The Team will demonstrate that […]
Strategies to strengthen scientific excellence and innoVation capacIty for early diagnoSIs of gastrOintestinal caNcers
Slovakia belongs to countries with the highest incidence of colorectal and pancreatic cancer in Europe. Therefore, the main goal of the VISION proposal is to strengthen the scientific excellence and […]
Towards a reliable assessment of nanomaterial health effects using advanced biological models and assays (NanoBioReal)
A sound scientific basis is needed to assess the risks to workers and consumers, to inform regulatory bodies and to ensure a responsible development of nanotechnology. Most of the existing […]
Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy (INNOCENT)
A challenge in the treatment of breast cancer patients is frequent relapses. This project focuses at circulating cancer stem cells, which are a main cause of relapses in the patients. The aim of this project is to develop a new drug for treatment of breast cancer, by targeting stem cells, based on nanoparticles.
Dr. Elise Rundén-Pran is senior scientist and section leader for Health Effects Laboratory and ERT registered toxicologist.
She has extensive experience in toxicology, nanotoxicology, nanosafety, cell cultures, 3D-cellular models, nanogenotoxicology, DNA damage, intracellular cell death signaling, microscopy (confocal, TEM), immunohistochemistry, tissue slice cultures and neurodegeneration.
She was part of the Centre for Excellence in Molecular Neurobiology and DNA repair (UiO) for several years (PhD and Postdoc). She is experienced with human risk assessment and regulatory toxicology, partner leader in EURONANOMED II projects GEMNS and INNOCENT, and NILU project leader for several projects funded by EU and NFR. She has extensive experience in GLP, and is appointed member of the national committee for approval of European registered toxicologists (ERT), The Norwegian Scientific Committee for Food and Environment, and member of the national expert group for toxicology.
The Health Effects Laboratory is certified for Good Laboratory Practice (GLP) for in vitro human toxicity studies. The laboratory is among the leading laboratories in Europe in nanotoxicology and nanosafety, and main areas of interest are genotoxicity, carcinogenicity in vitro, epigenetics, advanced in vitro models, regulatory aspects of nanosafety, high-throughput approach to toxicity testing, intelligent testing strategy and adverse outcome pathways.
Elise Rundén-Pran has 145 publications at NILU:
2025
2025
2025
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2022
2021
2021
2021
2021
2021
2021
2020
2020
2020
Risk governance of emerging technologies demonstrated in terms of its applicability to nanomaterials
2020
2020
2020
2020
2019
2019
2019
2019
2018
2017
2017
2017
2017
2017
2017
2017
2016
2016
2016
2016
2015
2015
2015
2014
2012
2011
2010
2009
2009
2009
Glutamate Oxaloacetate Transaminase Nanoparticles targeted to the Brain for Neuroprotection in Ischemic Stroke (GOTTARG)
The project will develop and test the first targeted and long-acting nanomedicine with neuroprotective properties for ischemic stroke, with potential application in other neurological diseases. The Team will demonstrate that […]
Strategies to strengthen scientific excellence and innoVation capacIty for early diagnoSIs of gastrOintestinal caNcers
Slovakia belongs to countries with the highest incidence of colorectal and pancreatic cancer in Europe. Therefore, the main goal of the VISION proposal is to strengthen the scientific excellence and […]
Towards a reliable assessment of nanomaterial health effects using advanced biological models and assays (NanoBioReal)
A sound scientific basis is needed to assess the risks to workers and consumers, to inform regulatory bodies and to ensure a responsible development of nanotechnology. Most of the existing […]
Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy (INNOCENT)
A challenge in the treatment of breast cancer patients is frequent relapses. This project focuses at circulating cancer stem cells, which are a main cause of relapses in the patients. The aim of this project is to develop a new drug for treatment of breast cancer, by targeting stem cells, based on nanoparticles.